New cocktail aims to knock out tough lymphoma

NCT ID NCT04231877

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to see how well they tolerate it. The goal is to find a more powerful upfront treatment for this fast-growing cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: polatuzumab vedotin (with or without glofitamab) plus standard chemotherapy (rituximab, etoposide, cyclophosphamide, doxorubicin, prednisone)
What this could lead to: If this combination is safe, it could lead to a more effective first treatment for aggressive B-cell lymphomas, potentially improving remission rates.
What could go wrong: This is a very early (Phase 1) safety study with only 56 people. The added drugs may cause more side effects, and it is not yet known if they work better than standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma ALK-positive large B-cell lymphoma B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma diffuse large B-cell lymphoma Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement primary mediastinal large B-cell lymphoma T-cell/histiocyte rich large B cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGGRESSIVE NON-HODGKIN LYMPHOMA ALK-POSITIVE LARGE B-CELL LYMPHOMA DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED GRAY ZONE LYMPHOMA HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.